Michael Kolodziej, MD, argues that clinical pathways as we know them will cease to exist as a result of the rise of immunotherapies for the treatment of cancer.
Richard Schilsky, MD kicked off the Clinical Pathways Congress discussing the relationship between clinical pathways development and emergence of precision medicine.
Journal of Clinical Pathways spoke with some of the experts who will be presenting at the inaugural Clinical Pathways Congress for a preview of the important topics they will be discussing at the meeting.
Find out more about the sessions scheduled at the inaugural Clinical Pathways Congress and when they are taking place. 
The inaugural Clinical Pathways Congress is here. Join JCP as we cover all the big sessions and events happening at this year’s meeting. 
J Russel Hoverman, MD, PhD, Texas Oncology, spoke about the performance of clinical pathways in practice.
James N Frame, MD, FACP, Charleston Area Medical Center, talked about some of the concerns that oncology care providers have about using clinical pathways.
Moderator Robin Zon, MD, FACP, FASCO, started off by providing a brief history of clinical pathways in oncology.